Pancreatic polypeptide (PP) has been shown to inhibit food intake in both rodents and humans. Acute peripheral administration of PP increases oxygen consumption in obese mice. To further investigate the function of PP in the modulation of energy balance, we examined its effects on spontaneous locomotor activity and food intake in mice by using a 24-chamber Comprehensive Laboratory Animal Monitoring System. Effects of intraperitoneal (i.p.) administration of PP on spontaneous locomotor activity were measured using the optical beam technique. Administration of PP dose dependently inhibited cumulative food intake. The inhibition remained significant for up to 6, 17 and 36 h at doses of 30, 100 and 300 nmol kg À1 PP, respectively. At 10 nmol kg À1 , PP increased locomotor activity (cumulative beam breaks) significantly for 4 h following administration without affecting food intake and at 30 nmol kg À1 , PP increased locomotor activity by 79% compared with the controls for 5 h post injection. However, at 100 and 300 nmol kg À1 , PP had no significant effect on locomotor activity. This study shows for the first time that PP increases spontaneous locomotor activity in mice.
Introduction
Pancreatic polypeptide (PP) is a 36-amino acid gut hormone belonging to the PP-fold peptide family. 1 In response to ingestion of food, PP is released from PP cells of the pancreatic islets in proportion to the calories ingested and the levels remain elevated for up to 6 h post prandially. 2 Circulating levels of PP have been reported to be lower in obese subjects 3, 4 and higher in patients with anorexia nervosa. 5, 6 Acute peripheral administration of PP reduces food intake in rodents and humans 7, 8 and repeated PP administration decreases body weight gain in obese mice. A single intraperitoneal (i.p.) injection of PP has been reported to increase oxygen consumption at 1-2 h following administration to obese mice in the early light phase. 9 These observations suggest that PP is involved in the regulation of energy balance.
Total energy expenditure consists of basal metabolic rate, the thermic effect of food and physical activity. 10 There is evidence to suggest that lean individuals have high levels of spontaneous physical activity (SPA) and obesity in different human populations is characterized by low levels of SPA. 11 It has also been reported that specific gut hormones affect SPA, in addition to their effects on food consumption. Ghrelin decreases spontaneous locomotor activity in rats, 12 and subcutaneous administration of oxyntomodulin increases physical activity-associated energy expenditure in overweight and obese humans. 13 However, it has not been reported whether administration of PP affects locomotor activity. To further elucidate the function of PP in the modulation of energy balance, we investigated its effects on spontaneous locomotor activity (measured as beam breaks) as well as food intake following peripheral administration. Effects of PP on food intake and activity Animals were monitored using a 24-chamber Comprehensive Laboratory Animal Monitoring System (Columbus Instruments, Columbus, OH, USA). Powdered chow (RM1 diet) and drinking water were available ad libitum. Mice were given a 2-day acclimatization period during which they received a daily i.p. injection of saline. During the studies, the horizontal ambulatory and vertical activity of each mouse was measured using the optical beam technique (Opto M3; Columbus Instruments). Activity was defined as more than two consecutive beam breaks. Cumulative beam breaks were recorded every 30 min. Food intake of each mouse was measured automatically through a computerized balance system attached to the food hopper and was recorded every 30 min.
Methods

Animals
Study 1: effects of PP (10 and 30 nmol kg À1 ) on food intake and locomotor activity in non-fasted mice Animals were randomized into three groups, given an i.p. injection of saline or PP at 10 or 30 nmol kg À1 immediately before the onset of the dark phase (1900 h) and then returned to their cages. Food intake and locomotor activity were measured for a period of 24 h following administration.
Study 2: effects of PP (100 and 300 nmol kg À1 ) on food intake and locomotor activity in non-fasted mice Animals were randomized into three groups, given an i.p. injection of saline or PP at 100 or 300 nmol kg À1 immediately before the onset of the dark phase (1900 h) and then returned to their cages. Food intake and locomotor activity were measured for a period of 36 h following administration.
Statistical analysis
Results are shown as mean±s.e.m. Statistical analysis was performed using a non-parametric two-sample Wilcoxon rank-sum (Mann-Whitney) test comparing the treatment group with the control group. In all cases, Po0.05 was considered to be statistically significant.
Results
Administration of PP at 10 nmol kg À1 had no significant effect on food intake ( Figure 1a) . Interestingly, 10 nmol kg
À1
of PP significantly increased horizontal ambulatory activity. The increase was significant from 1 h post injection (Po0.05) and was 59% above the controls by 4 h (0-4 h value: 2055 ± 211 for the saline group; 3270 ± 420 for the 10 nmol kg À1 PP treated; Po0.05). However, this increase was no longer significant by 5 h (Figure 1c) . Vertical movements were not affected (data not shown). Administration of PP at 30 nmol kg À1 significantly decreased cumulative food intake from 3 h post injection and the effect lasted up to 6 h (Po0.05; Figure 1a) . Moreover, 30 nmol kg À1 of PP significantly increased cumulative ambulatory activity by 79% compared with saline controls in the first 5 h period Figure 1c ). This effect was significant from 2.5 h post injection (Po0.05; Figure 1c ) but was not significant at any time points after 5 h post injection. Vertical movement was not significantly affected (data not shown). It appeared that the duration of the effects of PP at 30 nmol kg À1 on cumulative food intake and ambulatory activity was overlapping. The effects of PP on food intake and activity were then examined with a higher dose range. At 100 nmol kg
, PP caused significant reduction of cumulative food intake from 1.5 h post injection, which lasted up to 17 h. At 300 nmol kg À1 , PP significantly reduced cumulative food intake from 1.5 to 36 h post injection (Po0.05; Figure 2a ). However, locomotor activity was not significantly affected by either 100 or 300 nmol kg À1 of PP during the 36 h study period ( Figure 2b ).
Discussion
This study showed that i.p. administration of PP at 30, 100 and 300 nmol kg À1 significantly reduced cumulative food intake. The dose range used in this study is similar to that used in earlier studies. 9 However, at 10-100 nmol kg À1 , the anorectic effects of PP seemed to be less potent and shorter lived than previously reported. 9 This may be because of the fact that different strains of mice were used. In addition, this study was conducted in non-fasted animals using human PP, whereas Asakawa et al. 9 used mouse PP in fasted mice.
Nevertheless, at a dose of 30 nmol kg
À1
, PP was effective at suppressing food intake for up to 6 h. PP was administered at the beginning of the dark phase to ad libitum fed animals, as it is more physiologically relevant with regard to examining feeding behaviour and spontaneous activity.
We have shown for the first time that peripheral administration of PP at relatively low doses (10 or 30 nmol kg À1 ) increases locomotor activity. It has been reported that changes in the SPA directly predict resistance to fat mass accumulation during overfeeding in humans.
14 Reduced physical activity has also been found in diet-induced obese rodents. 15 It is interesting that the PP-induced increase in activity only occurred with the lower dose range, particularly at 10 nmol kg À1 which showed no significant effect on food intake. This disassociation of food intake and locomotor effects indicates that PP may exert these effects through different neuronal circuits. Circulating PP may inhibit food intake and promote locomotor activity through central mechanisms. There is evidence that PP activates neurons in the brainstem and hypothalamus through the Y4 receptor. 16 Peripherally administered PP reduces hypothalamic expression of the orexigenic neuropeptide Y, orexin and corticotropin-releasing factor, but increases expression of the anorexigenic neuropeptide urocortin. 9 Central administration of orexigenic neuropeptide Y has been reported to decrease SPA, 17 thus the stimulatory effects of PP on SPA may be attributed, at least in part, to a reduction in orexigenic neuropeptide Y signalling. Orexin 18 and corticotropin-releasing factor 19 increase SPA, suggesting that these molecules are unlikely to mediate the PP-induced increase in locomotor activity. However, urocortin has previously been demonstrated to increase activity and suppress food intake in rats following intracerebroventricular injection. 20 Urocortin is therefore another possible candidate for mediating the PP-induced increase in activity observed in this study. The increase in locomotor activity was not seen with 100 or 300 nmol kg À1 of PP. Comprehensive taste aversion tests have not been conducted in mice following peripheral PP administration. However, no obvious behavioural changes were observed in those animals and, in addition, we have found that PP does not cause abnormal behaviour at a dose of 1000 nmol kg À1 (Minnion J and Bloom SR, unpublished data). It is unclear why the effects of PP on locomotor activity are lost at higher doses. It has been previously reported that i.p. administration of PP caused a small, but significant increase in oxygen consumption in the early light phase in ob/ob mice without food, 9 indicating an increase in resting metabolic rate. The Pancreatic polypeptide and locomotor activity Y-L Liu et al current study does not provide evidence for activityassociated increase in energy expenditure, as oxygen consumption was not measured. It was anticipated that any increase in energy expenditure by an increase in spontaneous activity would be confounded by a reduction in food intake. Nevertheless, data from this study have given the first evidence that PP can affect spontaneous locomotor activity.
In conclusion, we have shown for the first time that PP increases spontaneous locomotor activity. The differential dose effects on locomotor activity and food intake suggest that PP may exert these effects through different neuronal circuits. Further studies are required to elucidate the mechanisms mediating the effects of PP on locomotor activity. Examination of activity-associated energy expenditure following chronic administration of PP may provide further insights to the role of PP in the modulation of energy balance.
